PMID- 38214148
OWN - NLM
STAT- MEDLINE
DCOM- 20240220
LR  - 20240220
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 62
IP  - 3
DP  - 2024 Mar
TI  - Subcutaneous infliximab CT-P13 without intravenous induction in psoriatic 
      arthritis: A case report and pharmacokinetic considerations.
PG  - 122-125
LID - 10.5414/CP204388 [doi]
AB  - INTRODUCTION: The biosimilar CT-P13, the first and only subcutaneous (SC) 
      infliximab formulation, is recommended for patients with psoriatic arthritis 
      (PsA) and can be administered as a maintenance treatment, to be started 4 weeks 
      after the induction treatment with 2 intravenous (IV) infliximab infusions. 
      OBJECTIVE: To evaluate treatment with SC infliximab without prior IV infusion 
      induction to meet patient needs. MATERIALS AND METHODS: After approval by the 
      ethics review board and based on the schedule approved for rheumatoid arthritis, 
      SC induction was performed with infliximab CT-P13 120 mg weekly for 4 weeks, 
      followed by an injection of 120 mg every 2 weeks. RESULTS: After 4 months of 
      therapy, joint symptoms were resolved, inflammation parameters were normalized 
      (erythrocyte sedimentation rate) reduced from 42 to 16 mm/h, and C-reactive 
      protein from 1.74 to 0.43 mg/dL), and clinical assessment parameters were 
      improved. After 9 months of therapy, the clinical data remained stable, with no 
      adverse events or local side effects. CONCLUSION: SC infliximab was successfully 
      used without previous IV infusion induction. Although, to date, the induction of 
      PsA treatment via the SC route is not foreseen, the known pharmacokinetic 
      properties and the outcome improvements observed in our patient show that 
      subcutaneous treatment induction, as is already done in the treatment of 
      rheumatoid arthritis, is also possible.
FAU - Ditto, Maria Chiara
AU  - Ditto MC
FAU - Parisi, Simone
AU  - Parisi S
FAU - Cotugno, Valentina
AU  - Cotugno V
FAU - Barila, Diego Antonio
AU  - Barila DA
FAU - Lo Sardo, Luca
AU  - Lo Sardo L
FAU - Cattel, Francesco
AU  - Cattel F
FAU - Fusaro, Enrico
AU  - Fusaro E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - B72HH48FLU (Infliximab)
RN  - 0 (CT-P13)
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Humans
MH  - Infliximab/adverse effects
MH  - *Arthritis, Psoriatic/drug therapy
MH  - Treatment Outcome
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - *Biosimilar Pharmaceuticals/adverse effects
MH  - *Antibodies, Monoclonal
EDAT- 2024/01/12 06:42
MHDA- 2024/02/20 11:51
CRDT- 2024/01/12 05:27
PHST- 2024/02/07 00:00 [accepted]
PHST- 2024/02/20 11:51 [medline]
PHST- 2024/01/12 06:42 [pubmed]
PHST- 2024/01/12 05:27 [entrez]
AID - 190881 [pii]
AID - 10.5414/CP204388 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2024 Mar;62(3):122-125. doi: 10.5414/CP204388.